FACTORS INFLUENCING THE OUTCOME OF THYROSTATIC DRUG-THERAPY IN GRAVES-DISEASE

被引:44
作者
WINSA, B
DAHLBERG, PA
JANSSON, R
AGREN, H
KARLSSON, FA
机构
[1] UNIV HOSP UPPSALA, DEPT INTERNAL MED, S-75185 UPPSALA, SWEDEN
[2] STOCKHOLM SJUKHEM, STOCKHOLM, SWEDEN
[3] UNIV HOSP UPPSALA, DEPT PSYCHIAT, S-75185 UPPSALA, SWEDEN
[4] CENT HOSP VASTERAS, VASTERAS, SWEDEN
来源
ACTA ENDOCRINOLOGICA | 1990年 / 122卷 / 06期
关键词
D O I
10.1530/acta.0.1220722
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In patients with Graves' disease, thyrostatic drug treatment may induce definitive remission without the need of more aggressive measures such as surgery or radioiodine. Following drug therapy, however, relapses often occur. In the present study, a multivariate analysis of pretreatment variables was performed, in order to identify individuals running a high risk of an unfavourable outcome of thyrostatic drug therapy. We studied 109 consecutive patients with a mean age of 38 years, range 20-70, over a mean follow-up period of 5.3 years after cessation of therapy. The analysis showed that goitre size, age, thyroid hormone levels, HLA-DR 3 haplotype, and TSH receptor antibody levels were of prognostic significance, whereas HLA-B8 haplotype, a lymphocytic infiltrate at fine needle biopsy, thyroglobulin, and microsomal antibodies had no such value. In particular, patients characterized by young age, large goitre and high hormone values were found to be associated with an unfavourable course.
引用
收藏
页码:722 / 728
页数:7
相关论文
共 33 条
[1]  
ALLANIC H, 1983, J CLIN ENDOCR METAB, V87, P139
[2]   LINKAGE OF HLA-DR-BETA SPECIFIC RESTRICTION FRAGMENT LENGTH POLYMORPHISMS WITH GRAVES-DISEASE [J].
BOEHM, BO ;
SCHIFFERDECKER, E ;
KUEHNL, P ;
SCHOFFLING, K .
ACTA ENDOCRINOLOGICA, 1988, 119 (02) :251-256
[3]   IMMUNE-MECHANISMS IN GRAVES-DISEASE [J].
BURMAN, KD ;
BAKER, JR .
ENDOCRINE REVIEWS, 1985, 6 (02) :183-232
[4]   LASTING REMISSIONS IN PATIENTS TREATED FOR GRAVES HYPERTHYROIDISM WITH PROPRANOLOL ALONE - A PATTERN OF SPONTANEOUS EVOLUTION OF THE DISEASE [J].
CODACCIONI, JL ;
ORGIAZZI, J ;
BLANC, P ;
PUGEAT, M ;
ROULIER, R ;
CARAYON, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1988, 67 (04) :656-662
[5]   THYROTROPIN-RELEASING-HORMONE TESTING DURING ANTITHYROID DRUG-TREATMENT OF GRAVES-DISEASE AS AN INDICATOR OF REMISSION [J].
DAHLBERG, PA ;
KARLSSON, FA ;
JANSSON, R ;
WIDE, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 61 (06) :1100-1104
[6]   HLA-A, HLA-B, HLA-C AND HLA-DR ANTIGENS IN PATIENTS WITH GRAVES-DISEASE AND THEIR CORRELATION WITH SIGNS AND CLINICAL COURSE [J].
DAHLBERG, PA ;
HOLMLUND, G ;
KARLSSON, FA ;
SAFWENBERG, J .
ACTA ENDOCRINOLOGICA, 1981, 97 (01) :42-47
[7]  
DAHLBERG PA, 1957, THYROID AUTOIMMUNITY, V24, P263
[8]   THYROTROPIN BINDING INHIBITING IMMUNOGLOBULINS IN GRAVES-DISEASE BEFORE, DURING AND AFTER ANTI-THYROID THERAPY, AND ITS RELATION TO LONG-ACTING THYROID-STIMULATOR [J].
DOCTER, R ;
BOS, G ;
VISSER, TJ ;
HENNEMANN, G .
CLINICAL ENDOCRINOLOGY, 1980, 12 (02) :143-153
[9]   REMISSION IN CHILDREN WITH HYPERTHYROIDISM TREATED WITH PROPYLTHIOURACIL - LONG-TERM RESULTS [J].
GORTON, C ;
SADEGHINEJAD, A ;
SENIOR, B .
AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1987, 141 (10) :1084-1086
[10]   THYROID-FUNCTION AND IMMUNOLOGICAL ACTIVITY DURING AND AFTER MEDICAL-TREATMENT OF GRAVES-DISEASE [J].
GOSSAGE, AAR ;
CRAWLEY, JCW ;
COPPING, S ;
HINGE, D ;
HIMSWORTH, RL .
CLINICAL ENDOCRINOLOGY, 1983, 19 (01) :87-96